Practice Guidelines

ACOG Releases Clinical Guidelines on Management of Menopausal Symptoms

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2014 Sep 1;90(5):338-340.

Key Points for Practice

  • Vasomotor symptoms are best managed with systemic HT, although alternatives such as SSRIs, SNRIs, and clonidine have been shown to be effective.

  • Vaginal symptoms are best treated with systemic or topical HT, but topical methods are preferable as they have fewer adverse effects.

  • Systemic HT should be given in the lowest dose and for the shortest period possible to decrease the risk of serious adverse events, such as thromboembolic disease and breast cancer.

From the AFP Editors

The median age of menopause in North America is 51 years. There is an array of menopausal symptoms; however, vasomotor and vaginal symptoms are the most closely related to hormonal changes during the transition to menopause. Hot flashes can last one to five minutes; can be characterized by perspiration, flushing, chills, clamminess, anxiety, and on occasion, heart palpitations; and can cause sleep disturbances. Vaginal atrophy results from the menopause-associated hypoestrogenic state and causes anatomic and physiologic changes in the genitourinary tract; symptoms include vaginal or vulvar dryness, discharge, itching, and dyspareunia. The American College of Obstetricians and Gynecologists (ACOG) has provided recommendations for the treatment of vasomotor and vaginal symptoms related to menopause.

Recommendations

BASED ON GOOD OR CONSISTENT EVIDENCE

Systemic estrogen hormone therapy (HT), with or without progestin, is the most effective therapy for menopause-related vasomotor symptoms, with evidence from multiple studies supporting the effectiveness. Oral and transdermal (i.e., patches, gels, or sprays) estrogen, alone or in combination with progestin, can be used, and have been shown to alleviate vasomotor symptoms (Table 1).

View/Print Table

Table 1.

Treatment Options for Menopausal Symptoms

BrandGenericRouteEffective dosageApproved for vasomotor symptoms?Approved for vaginal symptoms?

Climara

Estradiol

Transdermal

0.025 mg per day

Yes

Yes

Duavee

Conjugated estrogen/bazedoxifene

Oral

0.45 mg/20 mg per day

Yes

No

Estrace

Micronized estradiol-17β

Oral

0.5 to 1.0 mg per day

Yes

Yes

Estrace cream

Micronized estradiol-17β

Topical

2 g per day

No

Yes

Estring

Estradiol-17β ring

Vaginal ring

2 mg per 90-day ring

No

Yes

Femring

Estradiol acetate

Vaginal ring

0.05 mg per day

No

Yes

Osphena

Ospemifene

Oral

60 mg per day

No

Yes

Paxil

Paroxetine

Oral

7.5 mg per day

Yes

No

Premarin

Conjugated estrogen

Oral

0.3 to 0.625 mg per day

Yes

Yes

Premarin vaginal

Conjugated estrogen

Topical

0.5 to 2 g per day

No

Yes

Vagifem

Estradiol

Vaginal tablet

10 mcg per day

No

Yes


note: The American College of Obstetricians and Gynecologists guidelines mention other treatment options. Only those approved for this indication by the U.S. Food and Drug Administration are listed in this table.

Table 1.

Treatment Options for Menopausal Symptoms

BrandGenericRouteEffective dosageApproved for vasomotor symptoms?Approved for vaginal symptoms?

Climara

Estradiol

Transdermal

0.025 mg per day

Yes

Yes

Duavee

Conjugated estrogen/bazedoxifene

Oral

0.45 mg/20 mg per day

Yes

No

Estrace

Micronized estradiol-17β

Oral

0.5 to 1.0 mg per day

Yes

Yes

Estrace cream

Micronized estradiol-17β

Topical

2 g per day

No

Yes

Estring

Estradiol-17β ring

Vaginal ring

2 mg per 90-day ring

No

Yes

Femring

Estradiol acetate

Vaginal ring

0.05 mg per day

No

Yes

Osphena

Ospemifene

Oral

60 mg per day

No

Yes

Paxil

Paroxetine

Oral

7.5 mg per day

Yes

No

Premarin

Conjugated estrogen

Oral

0.3 to 0.625 mg per day

Yes

Yes

Premarin vaginal

Conjugated estrogen

Topical

0.5 to 2 g per day

No

Yes

Vagifem

Estradiol

Vaginal tablet

10 mcg per day

No

Yes


note: The American College of Obstetricians and Gynecologists guidelines mention other treatment options. Only those approved for this indication by the U.S. Food and Drug Administration are listed in this table.

Most women are able to tolerate HT; however, typical doses are associated with adverse effects (e.g., breast tenderness, vaginal bleeding, bloating, headaches). Low- and ultra low-dose estrogen may improve vasomotor symptoms in some women and have better adverse effect profiles compared with the typical doses. There have been limited studies comparing the efficacy of different dosing regimens, but the lower doses do not appear to be as effective as typical dosing. Some women may get significant relief from low-dose therapy, and thus treatment should be individualized. Patients should be treated with the lowest dose and for the shortest period possible to alleviate symptoms.

Thromboembolic disease and breast cancer are risks of combined HT. Most of the studies evaluating the safety of HT were of medications containing conjugated equine estrogen with or without medroxyprogesterone acetate. Other forms of estrogen and progestin may have different risks, such as a lower risk of venous thromboembolism with transdermal estrogen vs. oral estrogen (as indicated by some observational studies). More evidence is needed on the safety and effectiveness of various regimens compared with each other.

Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), clonidine (Catapres), and gabapentin (Neurontin) are effective nonhormonal medications for treating vasomotor symptoms, although paroxetine (Paxil) is the only nonhormonal medication approved by the U.S. Food and Drug Administration (FDA) for this indication. Adverse effects of SSRIs and SNRIs, which usually go away with time or with a change in dosage, include nausea, dizziness, dry mouth, nervousness, constipation, somnolence, sweating, and sexual dysfunction. Adverse effects of clonidine include dry mouth, insomnia, and drowsiness. Adverse effects of gabapentin include dizziness, somnolence, and peripheral edema.

Estrogen is effective for relieving menopause-related atrophic vaginal symptoms, and all low-dose estrogen is approved by the FDA for this indication. For women with only vaginal symptoms, local therapy is recommended.

Raloxifene (Evista) and tamoxifen, which are FDA-approved for prevention of osteoporosis and breast cancer, are not effective for the treatment of menopause-related vaginal symptoms; evidence does not indicate a significant effect of either for treating vasomotor symptoms. Studies indicate that ospemifene (Osphena), which is FDA-approved for treating moderate to severe dyspareunia in postmenopausal women, improves vaginal atrophy without stimulating the endometrium. Adverse effects of ospemifene include hot flashes, vaginal discharge, muscle spasms, genital discharge, and excessive sweating.

BASED ON LIMITED OR INCONSISTENT EVIDENCE

Data do not support progestin-only medications, testosterone, compounded bioidentical hormones, phytoestrogens, herbal supplements, or lifestyle modifications for the treatment of vasomotor symptoms. Although there are limited data regarding lifestyle modifications, reasonable options include layering clothing, maintaining a lower ambient temperature, drinking cool liquids, and avoiding alcohol and caffeine.

Nonestrogen water- or silicone-based vaginal lubricants and moisturizers may help with menopause-related vaginal symptoms and may be especially helpful in women wanting to avoid HT.

BASED ON CONSENSUS AND EXPERT OPINION

In approximately 50% of women on HT, regardless of age or duration of treatment, discontinuation of HT may cause vasomotor symptom recurrence. Data are insufficient to recommend one discontinuation approach over another (e.g., abrupt, tapering). Regardless of a woman's age, the choice to continue HT should be individualized and should be based on symptoms and the risk-to-benefit ratio.

Guideline source: American College of Obstetricians and Gynecologists

Evidence rating system used? Yes

Literature search described? Yes

Guideline developed by participants without relevant financial ties to industry? Not reported

Published source: Obstetrics & Gynecology, January 2014

Available at: http://journals.lww.com/greenjournal/Abstract/2014/01000/Practice_Bulletin_No__141___Management_of.37.aspx [subscription required]

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.

A collection of Practice Guidelines published in AFP is available at http://www.aafp.org/afp/practguide.



 

Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article